Cellectis SA (CLLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $118.86M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cellectis SA (CLLS) Stock Chart
Cellectis SA (CLLS) has a latest price of $1.06 on Nov 17, 2026, 80.6% below its 52-week high of $5.45. Its price fell 72.8% over the past 12 months. The month-end price fell 93.9% over the 10 years through Oct 2026, a compound annual decline of 24.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $35.01 in Oct 2017 and its lowest $0.97 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CLLS with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CLLS.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 66.6%, and over 6 months it fell 70.8%. The month-end price rose 11.3% over the 3 years through Oct 2026, a compound annual rate of 3.6%.
| Period | Change |
|---|---|
| 1 month | +14.5% |
| 3 months | -66.6% |
| 6 months | -70.8% |
| 12 months | -72.8% |
| 12 months, with dividends | -72.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +11.3% | +3.6% |
| 5 years | -90.0% | -36.9% |
| 10 years | -93.9% | -24.4% |
Price by Year
Its best calendar year was 2025, when the price rose 168.9%, and its weakest was 2022, when it fell 74.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.08 | -77.7% |
| 2025 | $4.84 | +168.9% |
| 2024 | $1.80 | -41.6% |
| 2023 | $3.08 | +46.7% |
| 2022 | $2.10 | -74.1% |
| 2021 | $8.12 | -70.0% |
| 2020 | $27.06 | +58.1% |
| 2019 | $17.12 | +2.8% |
| 2018 | $16.65 | -42.9% |
| 2017 | $29.15 | +72.0% |
Trading Range
The price is 22.1% below its 50-day average of $1.36 and 63.3% below its 200-day average of $2.89.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.06 | |
| 52-week high | $5.45 | -80.6% |
| 52-week low | $0.88 | +20.3% |
| 50-day average | $1.36 | -22.1% |
| 200-day average | $2.89 | -63.3% |
Price Risk
Over 3 years, its largest fall from a peak was 82.7%.
| Measure | Value |
|---|---|
| 1-year beta | 2.36 |
| Largest fall, 1 year | -82.7% |
| Largest fall, 3 years | -82.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CLLS
What is CLLS's 1-year price change?
Cellectis SA's price fell 72.8% over the past 12 months. With dividends included, the 12-month total return was -72.8%.
What is CLLS's 5-year price change?
Cellectis SA's month-end price fell 90.0% over the 5 years through Oct 2026, a compound annual decline of 36.9%. These figures leave out dividends.
What is CLLS's 52-week high and low?
Cellectis SA's 52-week high is $5.45 and its 52-week low is $0.88. Its latest price of $1.06 on Nov 17, 2026 is 80.6% below the high.
What is CLLS's beta?
Cellectis SA's 1-year beta against the S&P 500 is 2.36, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 82.7%.
Is the CLLS chart free?
Yes. Advanced Charting for CLLS is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CLLS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors